Interview with Martin Nelzow, CEO, Boehringer Ingelheim Brazil
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
The National Commission for the Incorporation of Technologies (CONITEC) deals with the incorporation of health technology within the scope of the Brazilian Unified Health System. (SUS) Conitec, assisted by the Department of Management and Incorporation of Technologies in Health aims to advise the Brazilian Ministry of Health in the attributions related to the incorporation, exclusion or alteration of health technologies by the SUS, as well as in the constitution or alteration of Clinical Protocols and Therapeutic Guidelines.
Contact:
Address: Ministry of Health Esplanada dos Ministérios G Block Brasília-DF / CEP: 70058-900
Tel.: +55 (61) 3315-2425
Website: http://conitec.gov.br/
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a…
Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could…
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which…
In an exclusive interview, Otto Philipp Braun, part of medtech giant B. Braun’s family dynasty, discusses his achievements as MD in Brazil, the company’s operations in the country and globally, as…
When we met you in 2007, as the head of the former Igefarma, the company was undergoing a transition – from branded generics into dermocosmetics and women’s health. But since…
Rogerio, you were one of the people responsible for integrating two well-established companies in the Brazilian market with the acquisition of Exel by DHL in late 2005. How challenging was…
You have 25 years of experience in the Brazilian pharmaceutical industry, witnessing the major transformations of this market and the fast emergence of generics. Regarding your background and experience at…
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What was it about Brazil…
With its huge market of 186 million people; its current position as the largest pharma market in Latin America, with strong growth projected; the influx of foreign and local…
See our Cookie Privacy Policy Here
